Medicalsystem Biotechnology Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Medicalsystem Biotechnology Co., Ltd. carries a market capitalization of 3.32B, placing it among publicly traded companies globally. Its enterprise value stands at 3.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.32B |
| Enterprise Value | 3.14B |
Share Statistics
Medicalsystem Biotechnology Co., Ltd. currently has 384.32M shares outstanding.
| Shares Outstanding | 384.32M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Medicalsystem Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 29.23. The price-to-sales ratio is 2.61, and the price-to-book ratio stands at 2.33.
| PE Ratio | 29.23 |
| PS Ratio | 2.61 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 1.42 |
| P/FCF Ratio | 10.63 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Medicalsystem Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 24.76 and an EV/FCF ratio of 8.36. The EV/Sales ratio of 2.06 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 24.76 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.06 |
| EV / EBITDA | 24.76 |
| EV / EBIT | 24.76 |
| EV / FCF | 8.36 |
Financial Position
Medicalsystem Biotechnology Co., Ltd. maintains a current ratio of 3.07, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.62, indicating elevated leverage, while an interest coverage ratio of 93.70 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.07 |
| Quick Ratio | 1.46 |
| Debt / Equity | 1.62 |
| Debt / EBITDA | 0.38 |
| Interest Coverage | 93.70 |
Financial Efficiency
Medicalsystem Biotechnology Co., Ltd. posts a return on equity of 8.13 and a return on invested capital of 4.24.
| Return on Equity (ROE) | 8.13 |
| Return on Assets (ROA) | 3.81 |
| Return on Invested Capital (ROIC) | 4.24 |
| Return on Capital Employed (ROCE) | 7.79 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.52 |
Taxes
Over the trailing twelve months, Medicalsystem Biotechnology Co., Ltd. has paid 4.64M in income taxes, reflecting an effective tax rate of 3.21.
| Income Tax | 4.64M |
| Effective Tax Rate | 3.21 |
Stock Price Statistics
Medicalsystem Biotechnology Co., Ltd.'s stock has declined approximately -18.50803% over the past 52 weeks. The 50-day moving average sits at 9.23, while the 200-day moving average is 9.96.
| Beta (5Y) | N/A |
| 52-Week Price Change | -18.50803% |
| 50-Day Moving Average | 9.23 |
| 200-Day Moving Average | 9.96 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Medicalsystem Biotechnology Co., Ltd. generated 1.53B in revenue and converted that into 136.37M in net income, yielding earnings per share of 0.37. EBITDA reached 126.97M, while operating income came in at 126.97M.
| Revenue | 1.53B |
| Gross Profit | 635.46M |
| Operating Income | 126.97M |
| Pretax Income | 144.59M |
| Net Income | 136.37M |
| EBITDA | 126.97M |
| EBIT | 126.97M |
| Earnings Per Share (EPS) | 0.37 |
Balance Sheet
Medicalsystem Biotechnology Co., Ltd. holds 882.93M in cash and equivalents against 47.63M in total debt, resulting in a net debt position of -687.70M. Total book value stands at 1.71B, with working capital of 1.25B providing operational flexibility.
| Cash & Cash Equivalents | 882.93M |
| Total Debt | 47.63M |
| Net Debt | -687.70M |
| Equity (Book Value) | 1.71B |
| Book Value Per Share | 4.51 |
| Working Capital | 1.25B |
Cash Flow
After subtracting -374.79M in capital expenditures, free cash flow totaled -374.79M - equivalent to -0.99 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -374.79M |
| Free Cash Flow | -374.79M |
| FCF Per Share | -0.99 |
Margins
Medicalsystem Biotechnology Co., Ltd. operates with a gross margin of 41.55, reflecting its pricing power and cost economics. The operating margin of 8.30 and net profit margin of 8.92 provide insight into operational efficiency.
| Gross Margin | 41.55 |
| Operating Margin | 8.30 |
| Pretax Margin | 9.45 |
| Profit Margin | 8.92 |
| EBITDA Margin | 8.30 |
Dividends & Yields
The company's payout ratio of 21.35 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.08 |
| Dividend Yield | N/A |
| Payout Ratio | 21.35 |
| Shareholder Yield | 1.90 |
| FCF Yield | 9.40 |
Stock Splits
Medicalsystem Biotechnology Co., Ltd.'s most recent stock split took place on September 17, 2015 with a 1:3 split ratio.
| Last Split Date | 9/17/2015 |
| Split Ratio | 1:3 |
Scores
Medicalsystem Biotechnology Co., Ltd. posts an Altman Z-Score of 4.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.87 |